Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial. [electronic resource]
Producer: 20171226Description: 1505-10 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab -- therapeutic use
- CA-125 Antigen -- genetics
- Disease Progression
- Disease-Free Survival
- Doxorubicin -- therapeutic use
- Drug Resistance, Neoplasm -- genetics
- Female
- Humans
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Ovarian Neoplasms -- drug therapy
- Platinum -- therapeutic use
- Prognosis
- Response Evaluation Criteria in Solid Tumors
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.